Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs Carfilzomib, Lenalidomide, and Dexamethasone vs Bortezomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase II Study
- Registry ID
- EUCTR2019-001645-41
- Source registry
- EUCTR
- Status
- Ongoing
- Phase
- PHASE2
- Sponsor
- Memorial Sloan Kettering Cancer center
- Start date
- 2020-03-27
- Last update
- 2026-08-16
Conditions
- Newly diagnosed Multiple Myeloma
Summary
The primary objective is to compare the rates of MRD negativity for patients who receive VRD (Arm A) to patients who receive KRD (Arm B) and for patients who received VRD (Arm A) to patients who received KRD + DARA (Arm C).
Locations
View on source registry